Efficacy of Switching From Teriparatide to Bisphosphonate or Denosumab: A Prospective, Randomized, Open-Label Trial

Overview

Journal JBMR Plus

Publisher Oxford University Press

Date 2018 Oct 5

PMID 30283910

Citations 16

Authors

Rui Niimi

Toshibumi Kono

Atsushi Nishihara

Masahiro Hasegawa

Toshihiko Kono

Akihiro Sudo

Affiliations

Soon will be listed here.

Abstract

There is no consensus on an optimal treatment after daily teriparatide (TPTD). We performed a prospective, randomized, open-label, 12-month trial to investigate the efficacy of follow-up treatment after daily TPTD treatment for Japanese patients. Three-hundred patients were enrolled in this study. Patients received oral bisphosphonate (BP) including alendronate (ALN; 35 mg/week) and minodoronate (MINO; 50 mg/month), or subcutaneous denosumab (60 mg/6 month). The primary efficacy measure was bone mineral density (BMD) responses in the lumbar spine (LS) and femoral neck (FN). Lumbar spine BMD increased by 1.3 ± 5.1% in the ALN subgroups, 0.5 ± 4.6% in the MINO subgroups, and 4.3 ± 3.5% in the denosumab subgroups. Femoral neck BMD increased by 0.7 ± 4.6% in the ALN subgroups, 0.2 ± 4.6% in the MINO subgroups, and 1.4 ± 3.4% in the denosumab subgroups. Lumbar spine BMD increases were significantly greater in the denosumab subgroup than the BP subgroups. There were no significant differences in FN BMD increases among the three subgroups. Lumbar spine BMD increases were significantly greater in the denosumab subgroup than the BP subgroups, whereas FN BMD increases were not significant. Denosumab treatment was more effective in increasing BMD and therefore has the potential benefit of fracture prevention. Further research is warranted to determine the optimal treatment after daily TPTD. © 2018 The Authors. published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.

Citing Articles

Efficacy and safety of sequential therapy for primary osteoporosis with bone formation promoters followed by bone resorption inhibitors: a meta-analysis.

Liu Y, Liu X, Wu Y, Luo T J Orthop Surg Res. 2025; 20(1):147.

PMID: 39920732 PMC: 11803957. DOI: 10.1186/s13018-025-05545-1.

Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Wells G, Hsieh S, Peterson J, Zheng C, Kelly S, Shea B Cochrane Database Syst Rev. 2025; 1:CD001155.

PMID: 39868546 PMC: 11770842. DOI: 10.1002/14651858.CD001155.pub3.

Therapy with transitions from one bone-forming agent to another: a retrospective cohort study on teriparatide and romosozumab.

Kobayakawa T, Kanayama Y, Hirano Y, Yukishima T, Nakamura Y JBMR Plus. 2024; 8(12):ziae131.

PMID: 39605880 PMC: 11601723. DOI: 10.1093/jbmrpl/ziae131.

Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.

Kobayashi T, Morimoto T, Ito K, Mawatari M, Shimazaki T Osteoporos Int. 2024; 35(8):1377-1393.

PMID: 38733394 DOI: 10.1007/s00198-024-07118-0.

Asia-Pacific consensus on long-term and sequential therapy for osteoporosis.

Tai T, Chen H, Shih C, Huang C, McCloskey E, Lee J Osteoporos Sarcopenia. 2024; 10(1):3-10.

PMID: 38690538 PMC: 11056428. DOI: 10.1016/j.afos.2024.02.001.

References

Niimi R, Nishihara A, Hasegawa M, Kono T, Sudo A . A retrospective analysis of nonresponse to daily teriparatide treatment. Osteoporos Int. 2016; 27(9):2845-2853. DOI: 10.1007/s00198-016-3581-z. View

Niimi R, Nishihara A, Hasegawa M, Matsumine A, Nakamura T, Kono T . An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide. Osteoporos Int. 2013; 25(1):377-84. DOI: 10.1007/s00198-013-2426-2. View

Lindsay R, Scheele W, Neer R, Pohl G, Adami S, Mautalen C . Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004; 164(18):2024-30. DOI: 10.1001/archinte.164.18.2024. View

Brown J, Prince R, Deal C, Recker R, Kiel D, de Gregorio L . Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2008; 24(1):153-61. DOI: 10.1359/jbmr.0809010. View

Adami S, San Martin J, Munoz-Torres M, Econs M, Xie L, Dalsky G . Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int. 2007; 19(1):87-94. DOI: 10.1007/s00198-007-0485-y. View

Niimi R, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A . Usefulness of daily teriparatide treatment in elderly patients over 80 years of age. Osteoporos Int. 2016; 27(5):1869-74. DOI: 10.1007/s00198-015-3479-1. View

Liberman U, Weiss S, Broll J, Minne H, Quan H, Bell N . Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333(22):1437-43. DOI: 10.1056/NEJM199511303332201. View

Niimi R, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A . Analysis of daily teriparatide treatment for osteoporosis in men. Osteoporos Int. 2015; 26(4):1303-9. DOI: 10.1007/s00198-014-3001-1. View

Leder B, Tsai J, Uihlein A, Wallace P, Lee H, Neer R . Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015; 386(9999):1147-55. PMC: 4620731. DOI: 10.1016/S0140-6736(15)61120-5. View

10.

Ebina K, Hashimoto J, Kashii M, Hirao M, Kaneshiro S, Noguchi T . The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab. 2016; 35(1):91-98. DOI: 10.1007/s00774-015-0731-x. View

11.

Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner M, Nakamura T . Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label.... Bone. 2010; 47(3):493-502. DOI: 10.1016/j.bone.2010.05.022. View

12.

Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T . A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone. 2009; 44(6):1078-84. DOI: 10.1016/j.bone.2009.02.016. View

13.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

14.

Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y . Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab. 2011; 30(4):439-46. PMC: 3396350. DOI: 10.1007/s00774-011-0332-2. View

15.

Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Kono T . Determinants associated with bone mineral density increase in response to daily teriparatide treatment in patients with osteoporosis. Bone. 2014; 66:26-30. DOI: 10.1016/j.bone.2014.05.017. View

16.

Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E . Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005; 20(9):1507-13. DOI: 10.1359/JBMR.050501. View